AI Summary
We reviewed 4 live results for kanjinti and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biosimilar and Oncology.
Comparison Table
Recommended
Kanjinti
Source: Amgen Biotechnology Singapore Pte Ltd
Description
Kanjinti is a trastuzumab biosimilar referencing Herceptin, approved in Singapore for treating HER2-overexpressing breast cancer and gastric cancer. This oncology therapy targets specific cancer cells to inhibit their growth, providing an essential treatment option within the local healthcare system.
Best for
HER2-positive breast cancer, gastric cancer therapy and oncology biosimilar preference
View Details
Rating
Kanjinti (Trastuzumab) 440 mg/vial
Source: Amgen
Description
Kanjinti is a high-dose 440 mg formulation of the trastuzumab biosimilar, indicated for patients with HER2-positive breast and gastric cancers. It works as a monoclonal antibody that inhibits the growth of tumor cells overexpressing the HER2 protein. Administered only by intravenous infusion, this prescription medication is registered in Singapore (SIN16207P) and is used in both early and metastatic stages of cancer therapy. The product is a biological medicine developed to meet the same quality, safety, and efficacy standards as the reference product.
Best for
metastatic breast cancer, high-dose trastuzumab therapy, HER2-positive gastric cancer and hospital-administered oncology
View Details
Rating
Kanjinti (Trastuzumab) 150 mg/vial
Source: Amgen
Description
Kanjinti is a biosimilar monoclonal antibody to the reference medicine Herceptin (trastuzumab). As a HER2/neu receptor antagonist, it is used for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. This 150 mg powder for injection vial is a prescription-only medicine (POM) typically administered via intravenous infusion in a clinical setting. It is registered in Singapore by the Health Sciences Authority (HSA) and listed in the National Drug Formulary for potential medical subsidies.
Best for
HER2-positive cancer patients, breast cancer treatment, gastric adenocarcinoma patients and oncology biosimilar cost-savings
View Details
Rating
| Compare | Kanjinti | Kanjinti (Trastuzumab) 440 mg/vial | Kanjinti (Trastuzumab) 150 mg/vial |
|---|---|---|---|
| Source | Amgen Biotechnology Singapore Pte Ltd | Amgen | Amgen |
| Description | Kanjinti is a trastuzumab biosimilar referencing Herceptin, approved in Singapore for treating HER2-overexpressing breast cancer and gastric cancer. This oncology therapy targets specific cancer cells to inhibit their growth, providing an essential treatment option within the local healthcare system. | Kanjinti is a high-dose 440 mg formulation of the trastuzumab biosimilar, indicated for patients with HER2-positive breast and gastric cancers. It works as a monoclonal antibody that inhibits the growth of tumor cells overexpressing the HER2 protein. Administered only by intravenous infusion, this prescription medication is registered in Singapore (SIN16207P) and is used in both early and metastatic stages of cancer therapy. The product is a biological medicine developed to meet the same quality, safety, and efficacy standards as the reference product. | Kanjinti is a biosimilar monoclonal antibody to the reference medicine Herceptin (trastuzumab). As a HER2/neu receptor antagonist, it is used for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. This 150 mg powder for injection vial is a prescription-only medicine (POM) typically administered via intravenous infusion in a clinical setting. It is registered in Singapore by the Health Sciences Authority (HSA) and listed in the National Drug Formulary for potential medical subsidies. |
| Best for | HER2-positive breast cancer, gastric cancer therapy and oncology biosimilar preference | metastatic breast cancer, high-dose trastuzumab therapy, HER2-positive gastric cancer and hospital-administered oncology | HER2-positive cancer patients, breast cancer treatment, gastric adenocarcinoma patients and oncology biosimilar cost-savings |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Kanjinti from Amgen Biotechnology Singapore Pte Ltd."
I picked this because Kanjinti is an HSA-registered trastuzumab biosimilar that offers a reliable and clinically effective oncology treatment for HER2-positive cancers.
Share this search
Related Finds